Hostname: page-component-745bb68f8f-kw2vx Total loading time: 0 Render date: 2025-01-22T11:44:17.090Z Has data issue: false hasContentIssue false
  • English
  • Français

Vagus Nerve Stimulation for Epilepsy: The Notre-Dame Hospital Experience

Published online by Cambridge University Press:  02 December 2014

Mehdi Qiabi ,
Alain Bouthillier ,
Lionel Carmant  and
Dang Khoa Nguyen
Mehdi Qiabi
Affiliation:
Division of Neurology, Montreal University Hospital Centre, Montreal, Quebec, Canada
Alain Bouthillier
Affiliation:
Division of Neurosurgery Notre-Dame Hospital, Montreal University Hospital Centre, Montreal, Quebec, Canada
Lionel Carmant
Affiliation:
Division of Neurology, Montreal University Hospital Centre, Montreal, Quebec, Canada
Dang Khoa Nguyen*
Affiliation:
Division of Neurology, Montreal University Hospital Centre, Montreal, Quebec, Canada
*
Neurology Service, Notre-Dame Hospital, 1560 rue Sherbrooke Est, Montréal, Québec, H2L 4M1, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Purpose:

Retrospective study assessing the efficacy and tolerability of vagus nerve stimulation (VNS) for the treatment of refractory epilepsy at Notre-Dame Hospital.

Methodology:

Chart review of all adult epileptic patients treated by VNS with ≥ 1 year follow-up. Responders were defined as patients with ≥ 50% reduction of baseline seizure frequency.

Results:

Thirty-four patients (14M; mean age = 29.9 yrs) received a VNS. Sub-pectoralis implantation (n = 25) was more frequent than subcutaneous (n = 9). Most patients suffered from intractable partial epilepsy. After 6 months, 12 months, 24 months, and 36 months, 14/34 patients (41%), 16/34 patients (47%), 17/30 patients (57%) and 12/20 patients (60%) respectively were responders. Two patients (6%) became seizure-free. Complications related to implantation were minor: eight cases of limited cervical hypoesthesia, two minor scar infections and one Horner syndrome. Adverse events (voice hoarseness, throat paresthesia, coughing) related to stimulation were generally mild and tended to wane over time. However, a reduction in seizure frequency did not translate into a reduction in medication, as only 9% of responders had less antiepileptic medication at last follow-up compared to baseline.

Conclusion:

VNS as practiced at Notre-Dame hospital is an efficacious and safe treatment for refractory epilepsy. Quotas allotted to epilepsy centers in the province of Quebec should be lifted or increased to allow more patients to benefit from this therapeutic device.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 6 , November 2011 , pp. 902 - 908
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1.Tellez-Zenteno, JF, Pondal-Sordo, M, Matijevic, S, Wiebe, S.National and regional prevalence of self-reported epilepsy in Canada. Epilepsia. 2004;45(12):1623–9.Google Scholar
2.Kwan, P, Brodie, MJ.Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–9.Google Scholar
3.So, EL, Bainbridge, J, Buchhalter, JR, et al.Report of the American Epilepsy Society and the Epilepsy Foundation joint task force on sudden unexplained death in epilepsy. Epilepsia. 2009;50(4):917–22.Google Scholar
4.Ben-Menachem, E, Manon-Espaillat, R, Ristanovic, R, et al.Vagus nerve stimulation for treatment of partial seizures. 1. A controlled study of effect on seizures. First International Vagus Nerve Study Group. Epilepsia. 1994;35(3):616–26.Google Scholar
5.Handforth, A, DeGiorgio, CM, Schachter, SC, et al.Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51(1):48–55.Google Scholar
6.Morris, GL, Mueller, WM.Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology. 1999;53(8):1731–5.Google Scholar
7.Rossignol, E, Lortie, A, Thomas, T, et al.Vagus nerve stimulation in pediatric epileptic syndromes. Seizure. 2009;18(1):34–7.Google Scholar
8.Nicholson, WJ, Tuohy, KA, Tilkemeier, P.Twiddler’s syndrome. N Engl J Med. 2003;348(17):1726–7.Google Scholar
9.Heck, C, Helmers, SL, DeGiorgio, CM.Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use. Neurology. 2002;59(6 Suppl 4):S31–7.Google Scholar
10.DeGiorgio, CM, Schachter, SC, Handforth, A, et al.Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia. 2000;41(9):1195–200.Google Scholar
11.Schachter, SC.Vagus nerve stimulation therapy summary. Five years after FDA approval. Neurology. 2002;59(6 Suppl 4):S15–20.CrossRefGoogle ScholarPubMed
12.Ardesch, JJ, Buschman, HP, Wagener-Schimmel, LJ, van der Aa, HE, Hageman, G.Vagus nerve stimulation for medically refractory epilepsy; a long-term follow-up study. Seizure. 2007;16(7):579–85.Google Scholar
13.Kuba, R, Brázdil, M, Kalina, M, et al.Vagus nerve stimulation: longitudinal follow-up of patients treated for 5 years. Seizure. 2009;18(4):269–74.Google Scholar
14.Boon, P, Vonck, K, Van Walleghem, P, et al.Programmed and magnet-induced vagus nerve stimulation for refractory epilepsy. J Clin Neurophysiol. 2001;18(5):402–7.Google Scholar
15.Scherrmann, J, Hoppe, C, Kral, T, et al.Vagus nerve stimulation: clinical experience in a large patient series. J Clin Neurophysiol. 2001;18(5):408–14.Google Scholar
16.Vonck, K, Thadani, V, Gilbert, K, et al.Vagus nerve stimulation for refractory epilepsy: a transatlantic experience. J Clin Neurophysiol. 2004;21(4):283–9.CrossRefGoogle ScholarPubMed
17.Amar, AP, Apuzzo, ML, Liu, CY.Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. Neurosurgery. 2004;55(5):1086–93.Google Scholar
18.De Herdt, V, Boon, P, Ceulemans, B, et al.Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study. Eur J Paediatr Neurol. 2007;11(5):261–9.Google Scholar
19.Muller, K, Fabo, D, Entz, L, et al.Outcome of vagus nerve stimulation for epilepsy in Budapest. Epilepsia. 2010;51(Suppl 3):98–101.Google Scholar
20.Ghaemi, K, Elsharkawy, AE, Schulz, R, et al.Vagus nerve stimulation: outcome and predictors of seizure freedom in long-term follow-up. Seizure. 2010;19(5):264–8.Google Scholar
21.Alonso-Vanegas, MA, Austria-Velásquez, J, López-Gómez, M, Brust-Mascher, E.Chronic intermittent vagal nerve stimulation in the treatment of refractory epilepsy: experience in Mexico with 35 cases. Cir Cir. 2010;78(1):15–23, 24.Google Scholar
22.Wheeler, M, De Herdt, V, Vonck, K, et al. Efficacy of vagus nerve stimulation for refractory epilepsy among patient subgroups: A re-analysis using the Engel classification. Seizure. 2011 Jan 25. [Epub ahead of print]Google Scholar
23.El Tahry, R, De Herdt, V, Raedt, R, et al.Evolution in VNS therapy for refractory epilepsy, experience with Demipulse devices at Ghent University Hospital. Seizure. 2010;19(9):531–5.Google Scholar
24.Franzoni, E, Gentile, V, Colonelli, MC, et al.VNS in drug resistant epilepsy: preliminary report on a small group of patients. Ital J Pediatr. 2010;36:30.Google Scholar
25.Guberman, A.Vagus nerve stimulation in the treatment of epilepsy. CMAJ. 2004;171(10):1165–6.Google Scholar
26.Ho, C, Li, H, Noorani, H, et al.Implantable cardiac defibrillators for primary prevention of sudden cardiac death in high risk patients: a meta-analysis of clinical efficacy, and a review of cost-effectiveness and psychosocial issues [Technology report no 81]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.Google Scholar
27.Groupe d’experts en électrophysiologie cardiaque du réseau québécois de cardiologie tertiaire. Évaluation des besoins: tendances et projections 2007-2010. Québec: La Direction des communications du ministère de la Santé et des Services sociaux du Québec; 2007 Nov. 51 p.Google Scholar
28.Renfroe, JB, Wheless, JW.Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology. 2002;59(6 Suppl 4):S26–30.Google Scholar
29.Boon, P, D’Havé, M, VanWalleghem, P, et al.Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia. 2002;43(1):96–102.Google Scholar
30.Ben-Menachem, E, Hellström, K, Verstappen, D.Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology. 2002;59(6 Suppl 4):S44–7.Google Scholar
31.Ben-Menachem, E.Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol. 2002;1(8):477–82. Review.Google Scholar
32.Fisher, R, Salanova, V, Witt, Tet al.and the SANTE study group. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51:899–908.Google Scholar
33.Morrell, MJ and the RNS System Pivotal Investigators. Results of a multicenter double blinded randomized controlled pivotal investigation of the RNS system for treatment of intractable partial epilepsy in adults [abstract]. Epilepsia. 2009;50(Suppl. 11):1–502.Google Scholar